- Home
- IVP vs SCNI Comparison
IVP vs SCNI Comparison
Compare IVP & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVP
- SCNI
- Stock Information
- Founded
- IVP 2020
- SCNI 2003
- Country
- IVP United States
- SCNI Israel
- Employees
- IVP N/A
- SCNI N/A
- Industry
- IVP Diversified Commercial Services
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IVP Miscellaneous
- SCNI Health Care
- Exchange
- IVP Nasdaq
- SCNI Nasdaq
- Market Cap
- IVP 3.0M
- SCNI 2.8M
- IPO Year
- IVP 2023
- SCNI N/A
- Fundamental
- Price
- IVP $2.08
- SCNI $3.52
- Analyst Decision
- IVP
- SCNI
- Analyst Count
- IVP 0
- SCNI 0
- Target Price
- IVP N/A
- SCNI N/A
- AVG Volume (30 Days)
- IVP 139.9K
- SCNI 20.5K
- Earning Date
- IVP 04-07-2025
- SCNI 11-22-2024
- Dividend Yield
- IVP N/A
- SCNI N/A
- EPS Growth
- IVP N/A
- SCNI N/A
- EPS
- IVP N/A
- SCNI 8.20
- Revenue
- IVP $17,054,777.00
- SCNI $452,000.00
- Revenue This Year
- IVP N/A
- SCNI N/A
- Revenue Next Year
- IVP N/A
- SCNI N/A
- P/E Ratio
- IVP N/A
- SCNI $0.43
- Revenue Growth
- IVP 6.12
- SCNI N/A
- 52 Week Low
- IVP $2.00
- SCNI $2.23
- 52 Week High
- IVP $401.50
- SCNI $8.92
- Technical
- Relative Strength Index (RSI)
- IVP 26.11
- SCNI 52.91
- Support Level
- IVP $2.03
- SCNI $3.30
- Resistance Level
- IVP $2.20
- SCNI $3.60
- Average True Range (ATR)
- IVP 0.19
- SCNI 0.25
- MACD
- IVP 0.07
- SCNI -0.01
- Stochastic Oscillator
- IVP 11.19
- SCNI 44.05
About IVP Inspire Veterinary Partners Inc.
Inspire Veterinary Partners Inc owns and operates veterinary hospitals throughout the United States. The company specializes in small animal general practice hospitals that serve all manner of companion pets, emphasizing canine and feline breeds.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.